High-Dose Furmonertinib in Patients With EGFR-Mutated NSCLC and Leptomeningeal Metastases: A Prospective Real-World Study
In the real world, the high-dose furmonertinib-based treatment may potentially have clinical efficacy and tolerable safety in patients of EGFR-mutated NSCLC with LM, even in patients previously treated with other third-generation EGFR TKIs. Methylation and copy number burden analysis of cfDNA in CSF may be considered objective indicators for the diagnosis of LM and evaluation of treatment response.
Authors
- Yingxi Wu
- Haoran Tang (ORCID: https://orcid.org/0009-0007-1805-0101)
- Dong Hang (ORCID: https://orcid.org/0000-0001-6944-0459)
- Sen Yang (ORCID: https://orcid.org/0000-0003-4177-0653)
- Yang Liu (ORCID: https://orcid.org/0000-0002-0367-8189)
- Qiming Wang (ORCID: https://orcid.org/0000-0003-3217-1077)
- Zhen He (ORCID: https://orcid.org/0000-0001-9972-9114)
- Lili Wang (ORCID: https://orcid.org/0000-0002-0474-9145)
- Cuicui Zhang (ORCID: https://orcid.org/0000-0001-5263-4345)
- Shuxiang Ma
- Yufeng Wu
- Haiyang Chen
Institutions
- Shanghai Medical College of Fudan University (CN)
- Zhengzhou University (CN)
- Henan Cancer Hospital (CN)
Publication Details
- Journal
- Journal of Thoracic Oncology
- Published
- 2024-09-10
- DOI
- https://doi.org/10.1016/j.jtho.2024.09.1385
- Citations
- 29
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 12.15
Funders
- Health Commission of Henan Province
- Science and Technology Department, Henan Province
- Science and Technology Department of Henan Province
- Wu Jieping Medical Foundation